Literature DB >> 21969987

Survival models in health economic evaluations: balancing fit and parsimony to improve prediction.

Christopher H Jackson1, Linda D Sharples, Simon G Thompson.   

Abstract

Health economic decision models compare costs and health effects of different interventions over the long term and usually incorporate survival data. Since survival is often extrapolated beyond the range of the data, inaccurate model specification can result in very different policy decisions. However, in this area, flexible survival models are rarely considered, and model uncertainty is rarely accounted for. In this article, various survival distributions are applied in a decision model for oral cancer screening. Flexible parametric models are compared with Bayesian semiparametric models, in which the baseline hazard can be made arbitrarily complex while still enabling survival to be extrapolated. A fully Bayesian framework is used for all models so that uncertainties can be easily incorporated in estimates of long-term costs and effects. The fit and predictive ability of both parametric and semiparametric models are compared using the deviance information criterion in order to account for model uncertainty in the cost-effectiveness analysis. Under the Bayesian semiparametric models, some smoothing of the hazard function is required to obtain adequate predictive ability and avoid sensitivity to the choice of prior. We determine that one flexible parametric survival model fits substantially better than the others considered in the oral cancer example.

Entities:  

Mesh:

Year:  2010        PMID: 21969987     DOI: 10.2202/1557-4679.1269

Source DB:  PubMed          Journal:  Int J Biostat        ISSN: 1557-4679            Impact factor:   0.968


  12 in total

1.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.

Authors:  Salah Ghabri; Françoise F Hamers; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

2.  Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.

Authors:  Vakaramoko Diaby; Georges Adunlin; Alberto J Montero
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

Review 3.  Overview of parametric survival analysis for health-economic applications.

Authors:  K Jack Ishak; Noemi Kreif; Agnes Benedict; Noemi Muszbek
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

4.  Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Authors:  Jaclyn Beca; Don Husereau; Kelvin K W Chan; Neil Hawkins; Jeffrey S Hoch
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

5.  Survival extrapolation in the presence of cause specific hazards.

Authors:  Tatiana Benaglia; Christopher H Jackson; Linda D Sharples
Journal:  Stat Med       Date:  2014-11-20       Impact factor: 2.373

6.  Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study.

Authors:  Béranger Lueza; Audrey Mauguen; Jean-Pierre Pignon; Oliver Rivero-Arias; Julia Bonastre
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

7.  Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.

Authors:  Xiaohui Zeng; Jianhe Li; Liubao Peng; Yunhua Wang; Chongqing Tan; Gannong Chen; Xiaomin Wan; Qiong Lu; Lidan Yi
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

8.  Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.

Authors:  Béranger Lueza; Federico Rotolo; Julia Bonastre; Jean-Pierre Pignon; Stefan Michiels
Journal:  BMC Med Res Methodol       Date:  2016-03-29       Impact factor: 4.615

Review 9.  Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods.

Authors:  Christopher Jackson; John Stevens; Shijie Ren; Nick Latimer; Laura Bojke; Andrea Manca; Linda Sharples
Journal:  Med Decis Making       Date:  2016-07-10       Impact factor: 2.583

10.  Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival.

Authors:  P J Newcombe; H Raza Ali; F M Blows; E Provenzano; P D Pharoah; C Caldas; S Richardson
Journal:  Stat Methods Med Res       Date:  2016-09-30       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.